Advanced Search

 

Study ID Status Title Patient Level Data
VEG105290 Completed A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects with Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)
VEG105424 Completed An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination with FOLFOX 6 or CapeOx in Subjects with Colorectal Cancer
VEG105427 Completed A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks
VEG105430 Active not recruiting An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients
VEG107200 Completed A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients with Hepatocellular Cancer
VEG107769 Active not recruiting An open-label extension study to assess the safety and efficacy of pazopanib in subjects with renal cell carcinoma previously enrolled on protocol VEG105192
VEG108838 Completed A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer
VEG108925 Completed A phase I, Open label, Study of the safety, tolerability and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for the relapsed or refractory metastatic colorectal cancer
VEG109599 Completed A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Gemcitabine and Gemcitabine plus Cisplatin for Advanced Solid Tumors.
VEG109603 Completed A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics dose escalation of Pazopanib in Combination with Epirubicin or Doxorubicin for Advanced Solid Tumors
VEG109607 Completed A Phase I Study of Pazopanib in Combination with Either Erlotinib or Pemetrexed in Patients with Advanced Solid Tumors
VEG110190 Completed A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors
VEG110727 Completed A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
VEG20002 Completed Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
VEG20006 Completed A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients with Relapsed or Refractory Multiple Myeloma
VEG20007 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
VIA-001 Completed Cost-effectiveness of a combination of Fluticasone Propionate and Salmeterol Xinafoate in comparison with conventional therapies of bronchial asthma (VIANI Real life).
VIA-002 Completed Viani® forte Discus® Post Marketing Surveillance Study.
VIN10003 Completed The Phase I Absolute Bioavailability Study of Oral NAVELBINE (vinorelbine tartrate) in Patients with Solid Tumors.
VIN10004 Completed An Open-Label Study to Provide Continuing Treatment with NAVELBINE (vinorelbine tartrate) Soft Gelatin Capsules or Injection to Subjects with Solid Tumors.
VINA1001 Completed A Phase I, Open-Label, Randomized, Crossover Study of Oral and Intravenous NAVELBINE (vinorelbine tartrate) in Subjects with Malignant Solid Tumors and Varying Degrees of Hepatic Function.
VINA2004 Completed A Phase II, Open-Label, Prospective, Randomized, Controlled, Multicenter Study of Single Agent NAVELBINE (vinorelbine tartrate) Administered Orally or Administered Intravenously for the Treatment of Chemotherapy-Naïve Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy- Na ...
VLX103596 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection. Study Listed on ClinicalStudyDataRequest.com
VLX105832 Completed The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection Study Listed on ClinicalStudyDataRequest.com
VRA105345 Completed A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth extraction

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.